<DOC>
	<DOCNO>NCT02486484</DOCNO>
	<brief_summary>Background/aims : Aflibercept approve therapy neovascular macular degeneration ( AMD ) , diabetic macular edema ( DME ) , retinal vein occlusion retinal condition . Ziv-aflibercept also approve FDA extremely cost-effective relative expensive molecule aflibercept . In vitro vivo study detect toxicity retinal pigment epithelium cell use approve cancer protein , ziv-aflibercept . Ziv-aflibercept loss anti-VEGF activity keep 4Â°C polycarbonate syrinx 4 week . Similar bevacizumab , compound ziv-aflibercept would yield tremendous save compare aflibercept ranibizumab . Phase I study case report report untoward toxic effect attest clinical efficacy medication . Our purpose ascertain long-term safety efficacy various retinal disease intravitreal ziv-aflibercept . Methods : Prospectively , consecutive patient retinal disease require aflibercept ( AMD , DME , RVO , others ) undergo instead molecule ziv-aflibercept intravitreal injection 0.05 ml fresh filter ziv-aflibercept ( 1.25mg ) . Monitoring best-corrected visual acuity , intraocular inflammation , cataract progression , retinal structure spectral domain OCT do initially , one month , 6 month , 1 year , 2 year injection . Anticipated Results : Analyze sign retinal toxicity , intraocular inflammation , change lens status , together best correct visual acuity central foveal thickness 1 month , 6 month , 1 year 2 year . Anticipated Conclusions : Off label use ziv-aflibercept improves visual acuity without ocular toxicity offer cheaper alternative molecule aflibercept ( lucentis ) , especially third world similar bevacizumab .</brief_summary>
	<brief_title>Ziv-aflibercept Ocular Disease Requiring Anti-VEGF Injection</brief_title>
	<detailed_description>Ascertain long term safety efficacy ziv-aflibercept large variety ocular diseases long-term proven safety efficacy laboratory , phase one study isolate case report . Background Significance : Anti-VEGF therapy currently one mainstay therapy great number disease eye intravitreal injection antiVEGF number one procedure do office ophthalmology practice . The ophthalmic community currently 2 expensive antiVEGF approve FDA ocular use : Ranibizumab aflibercept . However prohibitive cost medication third world need repetitive use agent control eye disease , off-label use bevacizumab currently common anti-VEGF use worldwide equivalent therapeutic efficacy cost-effective superiority . Bevacizumab ranibizumab high affinity VEGF , aflibercept possess additional property . Aflibercept ( Eylea ; Regeneron , Tarrytown , New York , USA Bayer Healthcare , Leverkusen , Germany ) fusion protein consist Fc portion human immunoglobulin IgG1 extracellular domain vascular endothelial growth factor receptor ( VEGFR-2 VEGFR-1 ) , bind circulate vascular endothelial growth factor ( VEGF ) , thus act decoy receptor . Laboratory study clinical trial suggest aflibercept 's high binding affinity VEGF may impart great durability activity similar efficacy compare ranibizumab1 bevacizumab . Aflibercept approve Food Drug Administration ( FDA ) therapy wet age relate macular degeneration ( AMD ) , macular edema retinal vein occlusion diabetes.3 Ranibizumab give monthly , aflibercept give bimonthly 3 monthly injection eye wet AMD . Because high cost ranibizumab aflibercept , majority ophthalmologist worldwide tend treat patient bevacizumab major save patient . Commercially , much cheap yet identical fusion protein aflibercept ziv-aflibercept . Ziv-aflibercept ( Zaltrap , Sanofi-Aventis US , LLC , Bridgewater , NJ Regeneron Pharmaceuticals , Inc , Tarrytown , NY ) approve FDA August 2012 treatment metastatic colorectal carcinoma resistant oxiplatin-containing regimen . One may wonder ziv-aflibercept use instead aflibercept ophthalmic disorder . Hence need answer major safety concern : first difference osmolarity , second whether ziv-aflibercept could impair retinal function alter morphology6 . A preliminary study conduct use ziv-aflibercept patient exudative AMD diabetic macular edema ( DME ) poor vision . In addition , investigator test stability ziv-aflibercept period 4 week economic implication use compounded drug . Ziv-aflibercept supplied single-use vial 100 mg per 4 ml 200 mg per 8 ml formulate 25 mg/mL ziv-aflibercept polysorbate 20 ( 0.1 % ) , sodium chloride ( 100 mM ) , sodium citrate ( 5 mM ) , sodium phosphate ( 5 mM ) , sucrose ( 20 % ) , Water Injection USP , pH 6.2 . Eylea supply single-use , glass vial design deliver 0.05 mL ( 2mg ) aflibercept ( 40 mg/mL 10 mM sodium phosphate , 40 mM sodium chloride , 0.03 % polysorbate 20 , 5 % sucrose , pH 6.2 ) . Design Procedures : Procedure : inject intravitreal ziv-aflibercept accord publish protocol approve FDA ( PROTOCOL A PROTOCOL B , PROTOCOL C , PROTOCOL D , publish aflibercept protocols protocol approve study disease ) . Design : Prospective nonrandomized open label long-term interventional clinical study patient subfoveal CNV , extrafoveal CNV due AMD disease ( myopia , inflammatory , angioid streak , traumatic , idiopathic ) , DME , BVO CRVO-related macular edema , diabetic vitreous hemorrhage , disease require anti-VEGF therapy . The inclusion/exclusion criterion summarize table 1 2 . All patient sign study consent form off-label use intravitreal ziv-aflibercept approve FDA oncology molecule different osmolarity eye disease . Patients Methods Patients All patient sign study consent form off-label use intravitreal ziv-aflibercept . Pretreatment work Initial work-up include best-corrected visual acuity ( BCVA ) use ETDRS acuity chart , slit-lamp examination anterior segment , dilate fundus examination , fluorescein angiography . Pretreatment macular thickness measure ocular coherence tomography ( OCT ) eye . Intravitreal injection ziv-aflibercept The hospital pharmacy divide 4cc vial ziv-aflibercept ( ZALTRAP ) purchase Ophthalmology Department , twenty 1 cc syrinx use aseptic technique . Therefore , syringe contain 0.2 ml ziv-aflibercept . The syrinx store 4 degree Celsius longer 30 day . The eye treat prepared 5 % povidone-iodine solution . Topical Anesthesia administer . Using 30-gauge needle , 0.05 ml ziv-aflibercept inject intravitreally par plana 3.5 mm limbus . If intraocular pressure great 25 mmHg optic nerve head adequately perfuse 20 minute injection ( patient report poor vision hand motion le ) , paracentesis perform . There need either patch eye use topical antibiotic . Post-injection follow-up Patients examine every month injection . At visit , BCVA measure along slit-lamp examination anterior segment dilate fundus examination . OCT repeat follow-up . The patient follow per standard approach delineate aflibercept trial AMD DME . In case unusually recurrent CNV DME base OCT , fluorescein angiography , clinical examination decrease vision additional injection may do depend particular case beyond standard protocol . The total follow-up period extend study 24 month patient . Patients data collection span period 3 year . Main outcome The main outcome measure improvement visual acuity , decrease central retinal thickness , stability lesion size AMD retinopathy DME . The paired Student 's t-test , Chi-square test , Pearson correlation ANOVA use analyze data . Potential risk Potential risk due injection minimal . However patient 0.2 % risk eye infection . Retinal detachment vitreous hemorrhage extremely rare potential risk . No untoward effect expect aflibercept . From experience others , sign ocular toxicity note already treat eye . But investigator look sign cataract corneal toxicity . In addition , intraocular inflammation know occur rate 0.2 % anti-VEGF include aflibercept . Such case record treated anti-inflammatory agent . PROTOCOL A ( AMD ) adapt VIEW 1 VIEW 2 In eye wet AMD , involve eye treat every 4 week 3 initial monthly injection , every 8 week till year 1 . Patients evaluate monthly determine need treatment treat least every 12 week ( cap PRN regimen ) 2 . PROTOCOL B ( BVO ) adapt VIBRANT The recommended dosage CRVO monthly injection till month 6 monthly monitoring PRN dose PROTOCOL C ( CRVO ) adapt COPERNICUS GALILEO The recommended dosage CRVO monthly injection till month 6 monthly monitoring PRN dose PROTOCOL D ( DME ) adapt VISTA VIVID The recommended dosage DME treatment 5 initial monthly injection follow one injection every 8 week Subject identification , recruitment , compensation : Compensation participation : None ( Compensation relate 25 time save expensive drug ) . The department ophthalmology would cover cost complication study , i.e . like treat patient endophthalmitis necessary antibiotic intravitreal systemic . Subject identification : Each collaborator supply data initial patient keep patient anonymity full protection . Patient recruitment : Any patient candidate anti-VEGF therapy ocular disease offer form therapy : choroidal neovascularization kind ( age-related macular degeneration , myopia , inflammatory , angioid streak , trauma , laser induce , idiopathic ) maculopathy retinopathy diabetes mellitus , branch central retinal vein occlusion , occlusive anterior posterior pole disorder ( neovascular glaucoma , rubeosis iridis , corneal neovascularization , angry pterygium , surgical traumatic fibrovascular ingrowth ) , tumor-associated new vessel formation . Risk/benefit assessment : There risk endophthalmitis 0.2 % intraocular injection . Benefit visual restoration avoidance blindness outweigh risk Costs subject : The patient regular charge medication ( 100,000 LL 66 USD ) similar off-label use bevacizumab . Ranibizumab aflibercept dexamethasone implant cost 25 time , know ziv-aflibercept aflibercept represent molecule exactly . So investigators give patient active product lower price . This major difference ranibizumab bevacizumab ( different molecule ) 25 time cheap . Privacy , Data Storage Confidentiality : Confidentiality file maintain use cod data supervision Dr AMM . Reference subject code identity , demographic data , medical data enter study sheet maintain locked drawer Dr AMM , password-protected computer .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Retinal Neovascularization</mesh_term>
	<criteria>All condition require antiVEGF therapy 1 . All eye condition require antiVEGF therapy 2 . Ability understand sign consent form 3 . Ability come followup ( 2 year followup ) 4 . Acute form disease naÃ¯ve case 1 . Cardiovascular , cerebrovascular peripheral vascular event le 3 month prior enrollment 2 . Current infection eye conjunctivitis keratitis 3 . Current upper respiratory tract infection 4 . Fever active body infection 5 . Lifethreatening disease short survival 6. late presentation disease ( chronic end stage disease eye ) 7 . Inability sign inform consent 8 . Inability come followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>macular degeneration</keyword>
	<keyword>diabetic retinopathy</keyword>
	<keyword>macular edema</keyword>
	<keyword>retinal vein occlusion</keyword>
	<keyword>choroidal neovascularization</keyword>
</DOC>